ViroPharma PT Raised to $27.00 (VPHM)
Cowen and Company hoisted their price target on shares of ViroPharma (NASDAQ:VPHM) from $26.00 to $27.00 in a research note issued on Friday, AnalystRatingsNetwork.com reports. The firm currently has a “market perform” rating on the stock. Cowen and Company’s price objective suggests a potential downside of 30.77% from the stock’s previous close.
Shares of ViroPharma (NASDAQ:VPHM) traded up 0.48% on Friday, hitting $39.00. 815,007 shares of the company’s stock traded hands. ViroPharma has a 52 week low of $22.12 and a 52 week high of $39.56. The stock’s 50-day moving average is $39.03 and its 200-day moving average is $31.49. The company’s market cap is $2.555 billion.
ViroPharma (NASDAQ:VPHM) last announced its earnings results on Thursday, October 24th. The company reported $0.20 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.05 by $0.15. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $113.35 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. Analysts expect that ViroPharma will post $-0.76 EPS for the current fiscal year.
A number of other firms have also recently commented on VPHM. Analysts at Zacks upgraded shares of ViroPharma from a “neutral” rating to an “outperform” rating in a research note to investors on Wednesday, October 23rd. They now have a $46.00 price target on the stock. Separately, analysts at Mizuho downgraded shares of ViroPharma from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, October 9th. They now have a $39.00 price target on the stock. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $38.03.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.